Abstract
Cell and molecular biological studies of p53 functions over the past 30 years have been complemented in the past 20 years by studies that use genetically engineered mice. As expected, mice that have mutant Trp53 alleles usually develop cancers of various types more rapidly than their counterparts that have wild-type Trp53 genes. These mouse studies have been instrumental in providing important new insights into p53 tumour suppressor function. Such studies have been facilitated by the development of increasingly sophisticated genetic engineering approaches, which allow the more precise manipulation of p53 structure and function in a mammalian model.
Change history
01 October 2009
In the version of this article initially published online, in page 8, the sentence "For example, mammary gland–specific Wap1 (also known as Wfdc5)–Cre mice" was incorrect and should be "For example, mammary gland–specific Wap–Cre mice". This error has been corrected for the print, HTML and PDF versions of the article.
References
Finlay, C. A., Hinds, P. W. & Levine, A. J. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57, 1083–1093 (1989).
Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88, 323–331 (1997).
Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307–310 (2000).
Palmiter, R. D. & Brinster, R. L. Germ-line transformation of mice. Annu. Rev. Genet. 20, 465–499 (1986).
Capecchi, M. R. Altering the genome by homologous recombination. Science 244, 1288–1292 (1989).
Bradley, A., Ramirez-Solis, R., Zheng, H., Hasty, P. & Davis, A. Genetic manipulation of the mouse via gene targeting in embryonic stem cells. Ciba Found. Symp. 165, 256–69 (1992).
Lavigueur, A. et al. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell. Biol. 9, 3982–3991 (1989).
Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233–1238 (1990).
Srivastava, S., Zou, Z. Q., Pirollo, K., Blattner, W. & Chang, E. H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome. Nature 348, 747–749 (1990).
Varley, J. M. Germline TP53 mutations and Li–Fraumeni syndrome. Hum. Mutat. 21, 313–320 (2003).
Bachinski, L. L. et al. Genetic mapping of a third Li–Fraumeni syndrome predisposition locus to human chromosome 1q23. Cancer Res. 65, 427–431 (2005).
Donehower, L. A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215–221 (1992).
Tsukada, T. et al. Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene 8, 3313–3322 (1993).
Jacks, T. et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1–7 (1994).
Purdie, C. A. et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9, 603–609 (1994).
Lee, E. Y. et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359, 288–294 (1992).
Jacks, T. et al. Effects of an Rb mutation in the mouse. Nature 359, 295–300 (1992).
Matzuk, M. M., Finegold, M. J., Su, J. G., Hsueh, A. J. & Bradley, A. α-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 360, 313–319 (1992).
Armstrong, J. F., Kaufman, M. H., Harrison, D. J. & Clarke, A. R. High-frequency developmental abnormalities in p53-deficient mice. Curr. Biol. 5, 931–936 (1995).
Sah, V. P. et al. A subset of p53-deficient embryos exhibit exencephaly. Nature Genet. 10, 175–180 (1995).
Jones, S. N., Roe, A. E., Donehower, L. A. & Bradley, A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378, 206–208 (1995).
Montes de Oca Luna, R., Wagner, D. S. & Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203–206 (1995).
Marine, J. C. & Lozano, G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ. 5 Jun 2009 (doi: 10.1038/cdd.2009.68).
de Rozieres, S., Maya, R., Oren, M. & Lozano, G. The loss of mdm2 induces p53-mediated apoptosis. Oncogene 19, 1691–1697 (2000).
Donehower, L. A. The p53-deficient mouse: a model for basic and applied cancer studies. Semin. Cancer Biol. 7, 269–278 (1996).
Venkatachalam, S. et al. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/− mouse model in carcinogenicity testing. Toxicol. Pathol. 29, 147–154 (2001).
Knudson, A. G. Jr, Hethcote, H. W. & Brown, B. W. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc. Natl Acad. Sci. USA 72, 5116–5120 (1975).
Knudson, A. G. Jr. Genetics of human cancer. Annu. Rev. Genet. 20, 231–251 (1986).
Venkatachalam, S. et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 17, 4657–4667 (1998).
Blackburn, A. C. et al. Loss of heterozygosity occurs via mitotic recombination in Trp53+/− mice and associates with mammary tumor susceptibility of the BALB/c strain. Cancer Res. 64, 5140–5147 (2004).
Birch, J. M. et al. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li–Fraumeni syndrome. Oncogene 17, 1061–1068 (1998).
Attardi, L. D. & Donehower, L. A. Probing p53 biological functions through the use of genetically engineered mouse models. Mutat. Res. 576, 4–21 (2005).
Lozano, G. The oncogenic roles of p53 mutants in mouse models. Curr. Opin. Genet. Dev. 17, 66–70 (2007).
Johnson, T. M. & Attardi, L. D. Dissecting p53 tumor suppressor function in vivo through the analysis of genetically modified mice. Cell Death Differ. 13, 902–908 (2006).
Hill, R., Song, Y., Cardiff, R. D. & Van Dyke, T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 123, 1001–1011 (2005).
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A. & Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847–849 (1993).
Clarke, A. R. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849–852 (1993).
Sigal, A. & Rotter, V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 60, 6788–6793 (2000).
Brosh, R. & Rotter, V. When mutants gain new powers: news from the mutant p53 field. Nature Rev. Cancer 9, 701–713 (2009).
Cho, Y., Gorina, S., Jeffrey, P. D. & Pavletich, N. P. Crystal structure of a p53 tumor suppressor–DNA complex: understanding tumorigenic mutations. Science 265, 346–355 (1994).
Dittmer, D. et al. Gain of function mutations in p53. Nature Genet. 4, 42–46 (1993).
Liu, G. et al. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc. Natl Acad. Sci. USA 97, 4174–4179 (2000).
Lang, G. A. et al. Gain of function of a p53 hot spot mutation in a mouse model of Li–Fraumeni syndrome. Cell 119, 861–872 (2004).
Olive, K. P. et al. Mutant p53 gain of function in two mouse models of Li–Fraumeni syndrome. Cell 119, 847–860 (2004).
Terzian, T. et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 22, 1337–1344 (2008).
Ljungman, M. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia 2, 208–225 (2000).
Horn, H. F. & Vousden, K. H. Coping with stress: multiple ways to activate p53. Oncogene 26, 1306–1316 (2007).
Eischen, C. M. & Lozano, G. p53 and MDM2: antagonists or partners in crime? Cancer Cell 15, 161–162 (2009).
McDonnell, T. J. et al. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J. Pathol. 188, 322–328 (1999).
Kim, W. Y. & Sharpless, N. E. The regulation of INK4/ARF in cancer and aging. Cell 127, 265–275 (2006).
Polager, S. & Ginsberg, D. p53 and E2f: partners in life and death. Nature Rev. Cancer 9, 738–748 (2009).
Sherr, C. J. & DePinho, R. A. Cellular senescence: mitotic clock or culture shock? Cell 102, 407–410 (2000).
Flores, E. R. et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7, 363–373 (2005).
Liu, G. et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nature Genet. 36, 63–68 (2004).
el-Deiry, W. S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817–825 (1993).
Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M. & Smith, J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211, 90–98 (1994).
Barboza, J. A., Liu, G., Ju, Z., El-Naggar, A. K. & Lozano, G. p21 delays tumor onset by preservation of chromosomal stability. Proc. Natl Acad. Sci. USA 103, 19842–19847 (2006).
Iwakuma, T. & Lozano, G. Crippling p53 activities via knock-in mutations in mouse models. Oncogene 26, 2177–2184 (2007).
Toledo, F. & Wahl, G. M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nature Rev. Cancer 6, 909–923 (2006).
Sluss, H. K., Armata, H., Gallant, J. & Jones, S. N. Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol. Cell. Biol. 24, 976–984 (2004).
Armata, H. L., Garlick, D. S. & Sluss, H. K. The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression. Cancer Res. 67, 11696–11703 (2007).
MacPherson, D. et al. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J. 23, 3689–3699 (2004).
Chao, C., Herr, D., Chun, J. & Xu, Y. Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J. 25, 2615–2622 (2006).
Marino, S., Vooijs, M., van Der Gulden, H., Jonkers, J. & Berns, A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 14, 994–1004 (2000).
Martinez-Cruz, A. B. et al. Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. Cancer Res. 68, 683–692 (2008).
Berman, S. D. et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc. Natl Acad. Sci. USA 105, 11851–11856 (2008).
Lengner, C. J. et al. Osteoblast differentiation and skeletal development are regulated by Mdm2–p53 signaling. J. Cell. Biol. 172, 909–921 (2006).
Lin, S. C. et al. Somatic mutation of p53 leads to estrogen receptor α-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res. 64, 3525–3532 (2004).
Walkley, C. R. et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 22, 1662–1676 (2008).
Hinkal, G. W., Parikh, N. & Donehower, L. A. Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression. PLoS ONE 4, e6654 (2009).
Seibler, J. et al. Rapid generation of inducible mouse mutants. Nucleic Acids Res. 31, e12 (2003).
Wijnhoven, S. W. et al. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res. 65, 8166–8173 (2005).
Christophorou, M. A. et al. Temporal dissection of p53 function in vitro and in vivo. Nature Genet. 37, 718–726 (2005).
Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B. & Evan, G. I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443, 214–217 (2006).
Ringshausen, I., O'Shea, C. C., Finch, A. J., Swigart, L. B. & Evan, G. I. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10, 501–514 (2006).
Martins, C. P., Brown-Swigart, L. & Evan, G. I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323–1334 (2006).
Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656–660 (2007).
Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661–665 (2007).
Nicol, C. J., Harrison, M. L., Laposa, R. R., Gimelshtein, I. L. & Wells, P. G. A teratologic suppressor role for p53 in benzo(a)pyrene-treated transgenic p53-deficient mice. Nature Genet. 10, 181–187 (1995).
Norimura, T., Nomoto, S., Katsuki, M., Gondo, Y. & Kondo, S. p53-dependent apoptosis suppresses radiation-induced teratogenesis. Nature Med. 2, 577–580 (1996).
Wang, B. Involvement of p53-dependent apoptosis in radiation teratogenesis and in the radioadaptive response in the late organogenesis of mice. J. Radiat. Res. 42, 1–10 (2001).
Parant, J. et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nature Genet. 29, 92–95 (2001).
Finch, R. A. et al. mdmx is a negative regulator of p53 activity in vivo. Cancer Res. 62, 3221–3225 (2002).
Hu, W., Feng, Z., Teresky, A. K. & Levine, A. J. p53 regulates maternal reproduction through LIF. Nature 450, 721–724 (2007).
Kay, C., Jeyendran, R. S. & Coulam, C. B. p53 tumour suppressor gene polymorphism is associated with recurrent implantation failure. Reprod. Biomed. Online 13, 492–496 (2006).
Hu, W., Feng, Z., Atwal, G. S. & Levine, A. J. p53: a new player in reproduction. Cell Cycle 7, 848–852 (2008).
de Vries, A. et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc. Natl Acad. Sci. USA 99, 2948–2953 (2002).
Tyner, S. D. et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 415, 45–53 (2002).
Maier, B. et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev. 18, 306–319 (2004).
Garcia-Cao, I. et al. “Super p53” mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21, 6225–6235 (2002).
Matheu, A. et al. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 448, 375–379 (2007).
Tomas-Loba, A. et al. Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell 135, 609–622 (2008).
Mendrysa, S. M. et al. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev. 20, 16–21 (2006).
Ferbeyre, G. & Lowe, S. W. The price of tumour suppression? Nature 415, 26–27 (2002).
Serrano, M. & Blasco, M. A. Cancer and ageing: convergent and divergent mechanisms. Nature Rev. Mol. Cell Biol. 8, 715–722 (2007).
Dumble, M. et al. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood 109, 1736–1742 (2007).
Liu, Y. et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 4, 37–48 (2009).
Akala, O. O. et al. Long-term haematopoietic reconstitution by Trp53−/−p16 Ink4A−/−p19 Arf−/− multipotent progenitors. Nature 453, 228–232 (2008).
Zheng, H. et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455, 1129–1133 (2008).
Gatza, C., Moore, L., Dumble, M. & Donehower, L. A. Tumor suppressor dosage regulates stem cell dynamics during aging. Cell Cycle 6, 52–55 (2007).
Bourdon, J. C. p53 Family isoforms. Curr. Pharm. Biotechnol. 8, 332–336 (2007).
Stiewe, T. The p53 family in differentiation and tumorigenesis. Nature Rev. Cancer 7, 165–168 (2007).
Mills, A. A. p63: oncogene or tumor suppressor? Curr. Opin. Genet. Dev. 16, 38–44 (2006).
Rosenbluth, J. M. & Pietenpol, J. A. The jury is in: p73 is a tumor suppressor after all. Genes Dev. 22, 2591–2595 (2008).
Mills, A. A. et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398, 708–713 (1999).
Yang, A. et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398, 714–718 (1999).
Keyes, W. M. et al. p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev. 19, 1986–1999 (2005).
Keyes, W. M. et al. p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc. Natl Acad. Sci. USA 103, 8435–8440 (2006).
Yang, A. et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404, 99–103 (2000).
Tomasini, R. et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 22, 2677–2691 (2008).
Tomasini, R., Mak, T. W. & Melino, G. The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol. 18, 244–252 (2008).
Kuperwasser, C. et al. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li—Fraumeni syndrome. Am. J. Pathol. 157, 2151–2159 (2000).
Harvey, M., McArthur, M. J., Montgomery, C. A. Jr, Bradley, A. & Donehower, L. A. Genetic background alters the spectrum of tumors that develop in p53- deficient mice. FASEB J. 7, 938–943 (1993).
Bruins, W. et al. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol. Cell. Biol. 24, 8884–8894 (2004).
Johnson, T. M., Hammond, E. M., Giaccia, A. & Attardi, L. D. The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nature Genet. 37, 145–152 (2005).
Nister, M. et al. p53 must be competent for transcriptional regulation to suppress tumor formation. Oncogene 24, 3563–3573 (2005).
Chao, C. et al. Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol. Cell. Biol. 26, 6859–6869 (2006).
Krummel, K. A., Lee, C. J., Toledo, F. & Wahl, G. M. The C-terminal lysines fine-tune p53 stress responses in a mouse model but are not required for stability control or transactivation. Proc. Natl Acad. Sci. USA 102, 10188–10193 (2005).
Luo, J. L. et al. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 20, 320–328 (2001).
Song, H., Hollstein, M. & Xu, Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nature Cell Biol. 9, 573–580 (2007).
Johnson, T. M., Meade, K., Pathak, N., Marques, M. R. & Attardi, L. D. Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence. Proc. Natl Acad. Sci. USA 105, 1215–1220 (2008).
Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nature Genet. 29, 418–425 (2001).
Ghebranious, N. & Sell, S. The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice. Hepatology 27, 967–973 (1998).
Li, B., Rosen, J. M., McMenamin-Balano, J., Muller, W. J. & Perkins, A. S. neu/ERBB2 cooperates with p53–172H during mammary tumorigenesis in transgenic mice. Mol. Cell. Biol. 17, 3155–3163 (1997).
Li, B. et al. Preferential overexpression of a 172Arg-->Leu mutant p53 in the mammary gland of transgenic mice results in altered lobuloalveolar development. Cell Growth Differ. 5, 711–721 (1994).
Hernandez, I. et al. Prostate-specific expression of p53R172L differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival. Mol. Cancer Res. 1, 1036–1047 (2003).
Duan, W. et al. Lung-specific expression of human mutant p53–273H is associated with a high frequency of lung adenocarcinoma in transgenic mice. Oncogene 21, 7831–7838 (2002).
Klein, M. A. et al. Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant. Oncogene 19, 5329–5337 (2000).
Godley, L. A. et al. Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys. Genes Dev. 10, 836–850 (1996).
Gillet, R. et al. The consequence of p53 overexpression for liver tumor development and the response of transformed murine hepatocytes to genotoxic agents. Oncogene 19, 3498–3507 (2000).
Kemp, C. J., Donehower, L. A., Bradley, A. & Balmain, A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74, 813–822 (1993).
Harvey, M. et al. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nature Genet. 5, 225–229 (1993).
Symonds, H. et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78, 703–711 (1994).
Howes, K. A. et al. Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev. 8, 1300–1310 (1994).
Schmitt, C. A. et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335–346 (2002).
Author information
Authors and Affiliations
Corresponding authors
Related links
Related links
DATABASES
NCI nature protein interaction Database (PID)
OMIM
FURTHER INFORMATION
Rights and permissions
About this article
Cite this article
Donehower, L., Lozano, G. 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 9, 831–841 (2009). https://doi.org/10.1038/nrc2731
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc2731
- Springer Nature Limited
This article is cited by
-
Targeting p53 gain-of-function activity in cancer therapy: a cautionary tale
Cell Death & Differentiation (2024)
-
Arsenic trioxide extends survival of Li–Fraumeni syndrome mimicking mouse
Cell Death & Disease (2023)
-
Porcine model elucidates function of p53 isoform in carcinogenesis and reveals novel circTP53 RNA
Oncogene (2021)
-
Single loss of a Trp53 allele triggers an increased oxidative, DNA damage and cytokine inflammatory responses through deregulation of IκBα expression
Cell Death & Disease (2021)
-
Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant
Nature Communications (2019)